News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
The Peripheral and Central Nervous System Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) meets today to review Vanda's New Drug Application (NDA) for tasimelteon, proposed trade name HETLIOZ, for the treatment of Non-24-Hour Disorder in the totally blind. The Advisory Committee meeting is scheduled for 8:00 am ET.
Vanda's HETLIOZ NDA is currently under Priority Review by the FDA with an action target date under the Prescription Drug User Fee Act (PDUFA-V) of January 31, 2014.
Investor Contact: Chad RubinVice PresidentThe Trout Group(646) firstname.lastname@example.org
Media Contact: Laney LandsmanAssistant Vice PresidentMakovsky(212) email@example.com
SOURCE Vanda Pharmaceuticals Inc.